Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital upgrades Genuit to 'outperform' on growth potential

(Sharecast News) - RBC Capital Markets upgraded Genuit on Wednesday to 'outperform' from 'sector perform' as it said the company was geared for growth. The bank said that Genuit - formerly Polypipe - is a high quality company with a strong management team, that is geared for growth as underlying markets are being revived by regulatory tailwinds through 2026E+.

"While we expect more of the same from underlying markets through year-end 2025E, 2026E should progressively improve with positive impacts from key regulatory drivers - the AMP8 program, the Future Homes/Buildings Standard, and the UK government new homes target," RBC said.

"With minor changes to our forecasts post H125 results and remaining cautious through year-end in expectation of another UK-government update in October, our discounted cash flow-based 505p price target is unchanged."

RBC said this was "a good entry point with GEN trading at 11x/10.2x C2025E/26E EV/adjusted EBIT, a discount to peers (13.8x/12.2x) and to its 5-year average of 12.5x".

Genuit makes plastic piping systems for use in the residential, commercial, civils and infrastructure sectors.

At 0835 BST, the shares were up 2.4% at 378.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.